Full year revenue and EBITDA in line with guidance Remain focused on post-COVID-19 growth strategy to become a leading global clinical diagnostics company in infectious diseases

Published date:

26/01/2023

Summary:

Paris, France and Eastleigh, UK – 26 January 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an unaudited trading update for the year ended 31 December 2022. Reported revenues and EBITDA for the period are both expected to be in line with guidance.

Paris, France and Eastleigh, UK – 26 January 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an unaudited trading update for the year ended 31 December 2022. Reported revenues and EBITDA for the period are both expected to be in line with guidance.

Financial highlights1

read more